O	0	11	Association
O	12	14	of
B-intervention	15	18	Low
I-intervention	18	19	-
I-intervention	19	22	Fat
I-intervention	23	30	Dietary
O	31	38	Pattern
O	39	43	With
O	44	50	Breast
O	51	57	Cancer
O	58	65	Overall
O	66	74	Survival
O	74	75	:
O	76	77	A
O	78	87	Secondary
O	88	96	Analysis
O	97	99	of
O	100	103	the
O	104	109	Women
O	109	110	'
O	110	111	s
O	112	118	Health
O	119	129	Initiative
O	130	140	Randomized
O	141	149	Clinical
O	150	155	Trial
O	155	156	.

O	157	159	In
O	160	161	a
O	162	172	randomized
O	173	181	clinical
O	182	187	trial
O	187	188	,
O	189	190	a
O	191	194	low
O	194	195	-
O	195	198	fat
O	199	205	eating
O	206	213	pattern
O	214	217	was
O	218	228	associated
O	229	233	with
O	234	239	lower
O	240	244	risk
O	245	247	of
O	248	253	death
O	254	259	after
O	260	266	breast
O	267	273	cancer
O	273	274	.

O	275	282	However
O	282	283	,
O	284	287	the
O	288	294	extent
O	295	297	to
O	298	303	which
O	304	311	results
O	312	316	were
O	317	323	driven
O	324	326	by
O	327	334	dietary
O	335	344	influence
O	345	347	on
O	348	356	survival
O	357	362	after
O	363	369	breast
O	370	376	cancer
O	377	386	diagnosis
O	387	390	was
O	391	398	unknown
O	398	399	.

O	400	402	To
O	403	412	determine
O	413	416	the
O	417	428	association
O	429	431	of
O	432	433	a
O	434	437	low
O	437	438	-
O	438	441	fat
O	442	449	dietary
O	450	457	pattern
O	458	462	with
O	463	469	breast
O	470	476	cancer
O	477	484	overall
O	485	493	survival
O	494	495	(
O	495	501	breast
O	502	508	cancer
O	509	517	followed
O	518	520	by
O	521	526	death
O	527	531	from
O	532	535	any
O	536	541	cause
O	542	550	measured
O	551	555	from
O	556	562	cancer
O	563	572	diagnosis
O	572	573	)
O	573	574	.

O	575	579	This
O	580	582	is
O	583	584	a
O	585	594	secondary
O	595	603	analysis
O	604	606	of
O	607	610	the
O	611	616	Women
O	616	617	'
O	617	618	s
O	619	625	Health
O	626	636	Initiative
O	637	647	randomized
O	648	656	clinical
O	657	662	trial
O	663	667	that
O	668	671	was
O	672	681	conducted
O	682	684	at
O	685	687	40
B-location	688	690	US
O	691	699	clinical
O	700	707	centers
O	708	717	enrolling
O	718	730	participants
O	731	735	from
O	736	740	1993
O	741	748	through
O	749	753	1998
O	753	754	.

O	755	767	Participants
O	768	772	were
B-total-participants	773	775	48
I-total-participants	776	779	835
B-eligibility	780	794	postmenopausal
I-eligibility	795	800	women
I-eligibility	801	805	with
I-eligibility	806	808	no
I-eligibility	809	817	previous
I-eligibility	818	824	breast
I-eligibility	825	831	cancer
I-eligibility	832	835	and
I-eligibility	836	843	dietary
I-eligibility	844	847	fat
I-eligibility	848	854	intake
I-eligibility	855	857	of
I-eligibility	858	865	greater
I-eligibility	866	870	than
I-eligibility	871	873	32
I-eligibility	873	874	%
I-eligibility	875	877	by
I-eligibility	878	882	food
I-eligibility	883	892	frequency
I-eligibility	893	906	questionnaire
O	906	907	.

O	908	920	Participants
O	921	925	were
O	926	936	randomized
O	937	939	to
O	940	941	a
O	942	949	dietary
O	950	962	intervention
O	963	968	group
O	969	970	(
O	970	972	40
O	972	973	%
O	973	974	;
O	975	976	n
O	977	978	=
B-intervention-participants	979	981	19
I-intervention-participants	982	985	541
O	985	986	)
O	987	991	with
O	992	997	goals
O	998	1000	to
O	1001	1007	reduce
O	1008	1011	fat
O	1012	1018	intake
O	1019	1021	to
O	1022	1024	20
O	1024	1025	%
O	1026	1028	of
O	1029	1035	energy
O	1036	1039	and
O	1040	1048	increase
O	1049	1054	fruit
O	1054	1055	,
O	1056	1065	vegetable
O	1065	1066	,
O	1067	1070	and
O	1071	1076	grain
O	1077	1083	intake
O	1084	1086	or
O	1087	1088	a
B-control	1089	1094	usual
I-control	1094	1095	-
I-control	1095	1099	diet
I-control	1100	1110	comparison
I-control	1111	1116	group
O	1117	1118	(
O	1118	1120	60
O	1120	1121	%
O	1121	1122	;
O	1123	1124	n
O	1125	1126	=
B-control-participants	1127	1129	29
I-control-participants	1130	1133	294
O	1133	1134	)
O	1134	1135	.

O	1136	1143	Dietary
O	1144	1149	group
O	1150	1162	participants
O	1163	1167	with
O	1168	1176	incident
O	1177	1183	breast
O	1184	1191	cancers
O	1192	1201	continued
O	1202	1204	to
O	1205	1216	participate
O	1217	1219	in
O	1220	1230	subsequent
O	1231	1238	dietary
O	1239	1251	intervention
O	1252	1262	activities
O	1262	1263	.

O	1264	1270	Breast
O	1271	1277	cancer
O	1278	1285	overall
O	1286	1294	survival
O	1295	1298	for
O	1299	1307	incident
O	1308	1314	breast
O	1315	1322	cancers
O	1323	1332	diagnosed
O	1333	1339	during
O	1340	1343	the
O	1344	1345	8
O	1345	1346	.
O	1346	1347	5
O	1347	1348	-
O	1348	1352	year
O	1353	1354	(
O	1354	1360	median
O	1360	1361	)
O	1362	1369	dietary
O	1370	1382	intervention
O	1382	1383	,
O	1384	1392	examined
O	1393	1395	in
O	1396	1400	post
O	1401	1404	hoc
O	1405	1413	analyses
O	1414	1419	after
O	1420	1422	11
O	1422	1423	.
O	1423	1424	5
O	1425	1430	years
O	1431	1432	(
O	1432	1438	median
O	1438	1439	)
O	1440	1453	postdiagnosis
O	1454	1460	follow
O	1460	1461	-
O	1461	1463	up
O	1463	1464	.

O	1465	1467	Of
O	1468	1472	1764
O	1473	1478	women
O	1479	1488	diagnosed
O	1489	1493	with
O	1494	1500	breast
O	1501	1507	cancer
O	1508	1514	during
O	1515	1518	the
O	1519	1526	dietary
O	1527	1539	intervention
O	1540	1546	period
O	1546	1547	,
O	1548	1552	mean
O	1553	1554	(
O	1554	1556	SD
O	1556	1557	)
O	1558	1561	age
O	1562	1564	at
O	1565	1574	screening
O	1575	1578	was
O	1579	1581	62
O	1581	1582	.
O	1582	1583	7
O	1584	1585	(
O	1585	1586	6
O	1586	1587	.
O	1587	1588	7
O	1588	1589	)
O	1590	1595	years
O	1596	1599	and
O	1600	1603	age
O	1604	1606	at
O	1607	1616	diagnosis
O	1617	1620	was
O	1621	1623	67
O	1623	1624	.
O	1624	1625	6
O	1626	1627	(
O	1627	1628	6
O	1628	1629	.
O	1629	1630	9
O	1630	1631	)
O	1632	1637	years
O	1637	1638	.

O	1639	1643	With
O	1644	1647	516
O	1648	1653	total
B-outcome	1654	1660	deaths
O	1660	1661	,
B-outcome	1662	1668	breast
I-outcome	1669	1675	cancer
I-outcome	1676	1683	overall
I-outcome	1684	1692	survival
O	1693	1696	was
O	1697	1710	significantly
O	1711	1718	greater
O	1719	1722	for
O	1723	1728	women
O	1729	1731	in
O	1732	1735	the
O	1736	1743	dietary
O	1744	1756	intervention
O	1757	1762	group
O	1763	1767	than
O	1768	1770	in
O	1771	1774	the
O	1775	1780	usual
O	1780	1781	-
O	1781	1785	diet
O	1786	1796	comparison
O	1797	1802	group
O	1803	1804	(
B-outcome	1804	1806	10
I-outcome	1806	1807	-
I-outcome	1807	1811	year
I-outcome	1812	1820	survival
O	1821	1823	of
B-iv-bin-percent	1824	1826	82
I-iv-bin-percent	1826	1827	%
O	1828	1831	and
B-cv-bin-percent	1832	1834	78
I-cv-bin-percent	1834	1835	%
O	1835	1836	,
O	1837	1849	respectively
O	1849	1850	;
O	1851	1857	hazard
O	1858	1863	ratio
O	1864	1865	[
O	1865	1867	HR
O	1867	1868	]
O	1868	1869	,
O	1870	1871	0
O	1871	1872	.
O	1872	1874	78
O	1874	1875	;
O	1876	1878	95
O	1878	1879	%
O	1880	1882	CI
O	1882	1883	,
O	1884	1885	0
O	1885	1886	.
O	1886	1888	65
O	1888	1889	-
O	1889	1890	0
O	1890	1891	.
O	1891	1893	94
O	1893	1894	;
O	1895	1896	P
O	1897	1898	=
O	1899	1900	.
O	1900	1902	01
O	1902	1903	)
O	1903	1904	.

O	1905	1907	In
O	1908	1911	the
O	1912	1919	dietary
O	1920	1925	group
O	1926	1931	there
O	1932	1936	were
O	1937	1942	fewer
B-outcome	1943	1949	deaths
I-outcome	1950	1954	from
I-outcome	1955	1961	breast
I-outcome	1962	1968	cancer
O	1969	1970	(
B-iv-bin-abs	1970	1972	68
O	1973	1975	vs
B-cv-bin-abs	1976	1979	120
O	1979	1980	;
O	1981	1983	HR
O	1983	1984	,
O	1985	1986	0
O	1986	1987	.
O	1987	1989	86
O	1989	1990	;
O	1991	1993	95
O	1993	1994	%
O	1995	1997	CI
O	1997	1998	,
O	1999	2000	0
O	2000	2001	.
O	2001	2003	64
O	2003	2004	-
O	2004	2005	1
O	2005	2006	.
O	2006	2008	17
O	2008	2009	)
O	2009	2010	,
B-outcome	2011	2016	other
I-outcome	2017	2024	cancers
O	2025	2026	(
B-iv-bin-abs	2026	2028	36
O	2029	2031	vs
B-cv-bin-abs	2032	2034	65
O	2034	2035	;
O	2036	2038	HR
O	2038	2039	,
O	2040	2041	0
O	2041	2042	.
O	2042	2044	76
O	2044	2045	;
O	2046	2048	95
O	2048	2049	%
O	2050	2052	CI
O	2052	2053	,
O	2054	2055	0
O	2055	2056	.
O	2056	2058	50
O	2058	2059	-
O	2059	2060	1
O	2060	2061	.
O	2061	2063	17
O	2063	2064	)
O	2064	2065	,
O	2066	2069	and
B-outcome	2070	2084	cardiovascular
I-outcome	2085	2092	disease
O	2093	2094	(
B-iv-bin-abs	2094	2096	27
O	2097	2099	vs
B-cv-bin-abs	2100	2102	64
O	2102	2103	;
O	2104	2106	HR
O	2106	2107	,
O	2108	2109	0
O	2109	2110	.
O	2110	2112	62
O	2112	2113	;
O	2114	2116	95
O	2116	2117	%
O	2118	2120	CI
O	2120	2121	,
O	2122	2123	0
O	2123	2124	.
O	2124	2126	39
O	2126	2127	-
O	2127	2128	0
O	2128	2129	.
O	2129	2131	99
O	2131	2132	)
O	2132	2133	.

O	2134	2136	In
O	2137	2142	women
O	2143	2146	who
O	2147	2155	received
O	2156	2157	a
O	2158	2167	diagnosis
O	2168	2170	of
O	2171	2177	breast
O	2178	2184	cancer
O	2185	2191	during
O	2192	2195	the
O	2196	2203	dietary
O	2204	2216	intervention
O	2217	2223	period
O	2223	2224	,
O	2225	2230	those
O	2231	2233	in
O	2234	2237	the
O	2238	2245	dietary
O	2246	2251	group
O	2252	2255	had
O	2256	2265	increased
B-outcome	2266	2273	overall
I-outcome	2274	2282	survival
O	2282	2283	.

O	2284	2287	The
O	2288	2296	increase
O	2297	2299	is
O	2300	2303	due
O	2303	2304	,
O	2305	2307	in
O	2308	2312	part
O	2312	2313	,
O	2314	2316	to
O	2317	2323	better
O	2324	2332	survival
O	2333	2337	from
O	2338	2345	several
O	2346	2352	causes
O	2353	2355	of
O	2356	2361	death
O	2361	2362	.

O	2363	2377	ClinicalTrials
O	2377	2378	.
O	2378	2381	gov
O	2382	2392	Identifier
O	2392	2393	:
O	2394	2405	NCT00000611
O	2405	2406	.
